Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2017
Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.
Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 64 citations in OpenAlex.
- Trial
- Next-Generation Sequencing for Minimal Residual Disease Detection in Pediatric Acute Lymphoblastic Leukemia: Technological Advances, Clinical Translations and Current Challenges.Current issues in molecular biology · 2026Review
- Minimal disease detection by immunoglobulin high-throughput sequencing in pediatric Burkitt lymphoma.Blood advances · 2026Article
- Secondary Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia Following Prolonged Lenalidomide Maintenance in Multiple Myeloma.Journal of medical cases · 2026Article
- Review
- Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts.Blood advances · 2025Review
- Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia.Annals of hematology · 2024Article
- Disparities in Acute Lymphocytic Leukemia Outcomes Among Young Adults.Journal of hematology · 2024Article
- Article
- [The progress in classification and prognosis evaluation of BCR::ABL1 positive acute lymphoblastic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.Journal of cancer research and clinical oncology · 2023Article
- Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.Haematologica · 2022Article
- MRD in ALL: Optimization and Innovations.Current hematologic malignancy reports · 2022Review
- Article
- Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.Leukemia · 2021Review
- Review
- Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation.Blood research · 2020Review
- Article
- Acute lymphoblastic leukemia clonal distribution between bone marrow and peripheral blood.Pediatric blood & cancer · 2020Article
- Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia.Leukemia · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
We used next-generation sequencing (NGS) of the immunoglobulin genes to evaluate residual disease in 153 specimens from 32 patients with adult B cell acute lymphoblastic leukemia enrolled in a single multicenter study. The sequencing results were compared with multiparameter flow cytometry (MFC) data in 66 specimens (25 patients) analyzed by both methods. There was a strong concordance (82%) between the methods in the qualitative determination of the presence of disease. However, in 17% of cases, leukemia was detected by sequencing but not by MFC. In 54 bone marrow (BM) and peripheral blood (PB) paired specimens, the burden of leukemia detected by NGS was lower in PB than in BM, although it was still detectable in 68% of the 28 paired specimens with positive BM. Lastly, patients without disease detected by NGS or MFC had a 5-year relapse free survival of > 80%. The results suggest that residual disease detection by immunoglobulin gene sequencing is an extremely sensitive technique and may identify patients that might benefit from transplantation. Moreover, the increased sensitivity of the method may allow frequent peripheral blood testing to supplement marrow sampling to measure disease response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.